Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

MapLight Therapeutics Announces $227M IPO, Advancing Neuropsychiatric Drug Pipeline

MapLight Therapeutics, a California-based biopharmaceutical company focused on neuropsychiatric therapies, has unveiled the terms of its initial public offering (IPO) in a recent regulatory filing. The company aims to raise $227.3 million by offering 14.7 million shares at $17 each on the Nasdaq under the ticker symbol MPLT. This move comes as a welcome development in the pharmaceutical industry, which has seen a slow year for IPOs in 2025.

NoahAI News10/8/2025

Pfizer Secures Metsera Acquisition Amid Fierce Competition

Pfizer has successfully acquired Metsera for $4.9 billion, outmaneuvering two other high-profile bidders in a competitive takeover process. The acquisition, which focuses on Metsera's promising obesity pipeline, showcases the pharmaceutical giant's strategic approach to expanding its portfolio in the highly lucrative obesity treatment market.

NoahAI News10/8/2025

Jupiter Endovascular Secures Over $40M in Series B Funding for Innovative Catheter Platform

Jupiter Endovascular, a startup spun out of Neptune Medical last year, has successfully raised more than its targeted $40 million in a Series B funding round. The company plans to utilize these funds to further develop and launch its groundbreaking TFX catheter platform, which is part of the Vertex system.

NoahAI News10/8/2025

Skye Bioscience's Obesity Drug Shows Mixed Results in Mid-Stage Trial

Skye Bioscience's experimental obesity drug nimacimab has yielded mixed results in a Phase IIa clinical trial, falling short of expectations as a monotherapy but showing promise when combined with Novo Nordisk's popular GLP-1 drug Wegovy. The findings, released on Monday, have sent shockwaves through the pharmaceutical industry and significantly impacted Skye's market value.

NoahAI News10/8/2025

MapLight Therapeutics Advances IPO Plans Amid Government Shutdown

MapLight Therapeutics, a biotechnology company developing drugs for neurological diseases, has set terms for its initial public offering (IPO) despite the ongoing federal government shutdown. The company is utilizing a regulatory workaround to advance its plans, highlighting the challenges faced by businesses seeking to go public during this period.

NoahAI News10/8/2025

Olympus and W.L. Gore Forge Global Distribution Partnership for Innovative Endoscopic Tool

Olympus, the Japanese medtech giant, has entered into a significant collaboration with U.S.-based W.L. Gore, securing international distribution rights for the Gore Viabil endoscopic placement tool. This strategic partnership, announced on October 6, 2025, aims to expand Olympus's global footprint in the rapidly growing gastrointestinal metal stent market.

NoahAI News10/8/2025

Qualtrics Acquires Press Ganey Forsta for $6.75 Billion, Expanding AI Capabilities in Healthcare

Customer experience firm Qualtrics has agreed to acquire healthcare market research company Press Ganey Forsta for $6.75 billion, marking a significant move in the healthcare technology sector. The deal, announced on Monday, aims to combine Qualtrics' artificial intelligence technology with Press Ganey's extensive healthcare data and expertise to develop new AI-powered tools and services.

NoahAI News10/8/2025

Tariff Threats Reshape Pharmaceutical Manufacturing Landscape

In the wake of President Donald Trump's tariff threats against the pharmaceutical industry, a new survey by research group CRB reveals a stark divide in how companies are responding to these economic pressures. The 2025 Horizons Life Sciences Report, which surveyed over 400 biopharma executives, paints a picture of an industry grappling with uncertainty and adapting to a changing global trade environment.

NoahAI News10/8/2025

Pharmaceutical Industry Faces Widespread Layoffs Amid Strategic Shifts and Financial Pressures

The pharmaceutical and biotech sectors are experiencing a significant wave of workforce reductions as companies across the industry implement cost-cutting measures and strategic realignments. From major players to smaller biotechs, organizations are trimming headcounts to extend cash runways and refocus on core priorities.

NoahAI News10/8/2025

OXB Expands US Footprint with $4.5M Acquisition of Viral Vector Plant from National Resilience

Oxford Biomedica (OXB), a leading cell and gene therapy manufacturer, has made a significant move to bolster its presence in the United States. The UK-based company has acquired a viral vector plant in North Carolina from National Resilience for $4.5 million, marking a crucial step in its US expansion strategy.

NoahAI News10/8/2025

GLD Partners Launches Altagenics to Target Muscle-Wasting Conditions

GLD Partners, a healthcare and biotech-focused investment firm, has announced the launch of Altagenics, a new biotechnology startup aimed at developing first-in-class medicines for muscle-wasting conditions. The venture, which leverages Heligenics' GigaAssay platform, marks a significant milestone in GLD's drug discovery strategy and represents a novel approach to addressing unmet medical needs in sarcopenia and cachexia.

NoahAI News10/8/2025

Convatec Announces $1 Billion Investment in R&D Facilities Across US and UK

Convatec, a leading provider of medical devices for chronic conditions, has unveiled plans to invest over $1 billion in research and development facilities in the United States and United Kingdom over the next decade. This significant commitment aims to bolster the company's innovation capabilities and strengthen its position in key markets.

NoahAI News10/8/2025

«1...49 50 51...67 »